ANDA 63181, held by Watson Labs Teva. Minocycline Hydrochloride.
As of Nov 22, 2026, ANDA 63181 (Minocycline Hydrochloride), held by Watson Labs Teva, was first approved by FDA on Dec 30, 1991, with 21 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 30, 1991 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Minocycline HydrochlorideEQ 50MG BASE ยท capsule;oral | Minocycline Hydrochloride | Rx |
| May 12, 2026 | Supplement 59Labeling ยท Standard review | Approved | None posted |
| May 12, 2026 | Supplement 58Labeling ยท Standard review | Approved | None posted |
| May 5, 2020 | Supplement 54Labeling ยท Standard review | Approved | None posted |
| May 5, 2020 | Supplement 53Labeling ยท Standard review | Approved | None posted |
| May 5, 2020 | Supplement 52Labeling ยท Standard review | Approved | None posted |
| Nov 20, 2008 | Supplement 40Labeling | Approved | None posted |
| May 29, 2008 | Supplement 36Labeling | Approved | None posted |
| Oct 16, 2001 | Supplement 18Labeling | Approved | None posted |
| Oct 16, 2001 | Supplement 17Manufacturing | Approved | None posted |
| Apr 25, 2001 | Supplement 16Manufacturing | Approved | None posted |
| Jun 7, 1999 | Supplement 15Manufacturing | Approved | None posted |
| Dec 9, 1998 | Supplement 13Manufacturing | Approved | None posted |
| May 12, 1998 | Supplement 9Manufacturing | Approved | None posted |
| May 12, 1998 | Supplement 8Manufacturing | Approved | None posted |
| Apr 7, 1998 | Supplement 12Manufacturing | Approved | None posted |
| Apr 7, 1998 | Supplement 11Manufacturing | Approved | None posted |
| Apr 7, 1998 | Supplement 10Manufacturing | Approved | None posted |
| Nov 5, 1997 | Supplement 7Manufacturing | Approved | None posted |
| May 8, 1996 | Supplement 5Labeling | Approved | None posted |
| Mar 4, 1996 | Supplement 3Labeling | Approved | None posted |
| Jul 22, 1992 | Supplement 1Manufacturing | Approved | None posted |
| Dec 30, 1991 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters